MWNA
CLSD

Marshall Wace North America’s Clearside Biomedical CLSD Stock Holding History

Marshall Wace North America’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-38,842
Closed -$3.58M – 1493
2018
Q3 		$3.58M Buy
38,842
+1,061
+3% +$126K 0.02% 382
2018
Q2 		$6.06M Sell
37,781
-19,337
-34% -$3.26M 0.03% 469
2018
Q1 		$9.19M Buy
57,118
+42,741
+297% +$5.21M 0.05% 416
2017
Q4 		$1.51M Hold
14,377
– – 0.01% 906
2017
Q3 		$1.94M Sell
14,377
-220
-2% -$26.9K 0.01% 803
2017
Q2 		$1.97M Buy
14,597
+267
+2% +$32.1K 0.01% 745
2017
Q1 		$1.72M Buy
+14,330
New +$1.69M 0.01% 606

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace North America's CLSD Position: Q4 2018 in Review

Marshall Wace North America sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 38,842 shares — an estimated $3.58M sold.

Marshall Wace North America first reported a position in CLSD in Q1 2017 and held it in 7 quarters. The position peaked at $9.19M in Q1 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

  • Marshall Wace North America reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
  • Marshall Wace North America sold 38,842 Clearside Biomedical shares in Q4 2018, an estimated $3.58M.
  • Marshall Wace North America first reported a position in Clearside Biomedical in Q1 2017 and held it in 7 quarters.
  • Marshall Wace North America's Clearside Biomedical position peaked at $9.19M in Q1 2018.
  • 69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Marshall Wace North America's 13F filing for Q4 2018, filed 14 Feb 2019.